AbCellera Biologics (ABCL) investor relations material

Company evolution and strategy

• Transitioned from a technology-driven discovery partner to a clinical-stage drug developer over 13 years, leveraging proprietary antibody discovery platforms.

• Secured significant non-dilutive capital (~CAD 1B) from pandemic response work and public offerings, enabling internal pipeline development.

• Shifted focus in 2023 to advancing in-house clinical assets, with a new company profile and increased investor engagement.

• Emphasizes best-in-class capabilities for GPCRs, ion channels, multispecifics, and ADCs, aiming for highly differentiated therapeutics.

• Plans to bring forward multiple clinical programs, with ABCL635 leading and ABCL688 and 386 expected to follow.

Lead programs and clinical outlook

• ABCL635 targets NK3R, aiming to offer efficacy comparable or superior to small molecules, with better safety and monthly dosing convenience.

• Interim phase I data show clean safety, no liver enzyme signals, and superior, sustained testosterone suppression compared to small molecules.

• Phase II readout in Q3 will focus on efficacy (targeting ~22% reduction in frequency vs. placebo) and safety to confirm differentiation.

• Market research indicates a strong patient and practitioner preference for monthly injectables over daily orals, especially given safety advantages.

• Being the only injectable in a market developed by small molecules is seen as a strategic advantage.

Pipeline and portfolio management

• ABCL575, an OX40 ligand antibody, is considered less strategic due to class setbacks but will be read out by year-end; partnering prospects in atopic dermatitis are limited.

• Focus remains on advancing ABCL635, 688 (autoimmunity, GPCR/ion channel), and 386 (oncology), with limited public disclosure to maintain competitive advantage.

• By 2027, aims to have multiple differentiated assets in late-stage development, demonstrating platform strength and strategic portfolio selection.

• Intends to keep pipeline details confidential until close to clinical entry, leveraging in-house manufacturing to delay patent filings.